Plexxikon

Plexxikon is an American drug discovery company based in Berkeley, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.

It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches.

In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[1][2][3]

Drug pipeline
  • Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[4] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[5]
  • PLX7486 is a CSF1R antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.[6][7]
gollark: Also it would have to run on 15W.
gollark: I don't see why you would want it? They couldn't really be extra cores which seem like they're on the same CPU. They would, as I said, have to be an effectively independent computer with some kind of high-bandwidth link to the main one.
gollark: That would also be very impractical, unless you make the "extra cores" basically a small independent computer with its own RAM and stuff.
gollark: Connect PCIe devices, mostly, which you can do now.
gollark: As far as I'm aware, the traces on the boards for the DIMMs have to be very precise lengths and stuff or the signals will get messed up.

References
  1. "Daiichi Sankyo to Acquire Plexxikon".
  2. "Plexxikon acquired by Daiichi Sankyo". Haberman Associates. 2011-03-03. Retrieved 2020-08-06.
  3. "Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition". BioSpace. Retrieved 2020-08-06.
  4. News on Wyeth collaboration
  5. PLX204 trial
  6. "Fms/Trk tyrosine kinase inhibitor PLX7486". NCI Drug Dictionary. National Cancer Institute.
  7. Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.